-
公开(公告)号：US20130210886A1
公开(公告)日：2013-08-15
申请号：US13809761
申请日：2011-07-29
申请人： Pierre-Olivier Vidalain , Marianne Lucas-Hourani , Frédéric Tangy , Héléne Munier-Lehmann , Daniel Dauzonne
发明人： Pierre-Olivier Vidalain , Marianne Lucas-Hourani , Frédéric Tangy , Héléne Munier-Lehmann , Daniel Dauzonne
IPC分类号： C07D307/83 , C07D493/04 , C07D405/02
CPC分类号： C07D307/83 , C07D307/82 , C07D405/02 , C07D405/04 , C07D493/04
摘要： The invention relates to compounds of formula (I) for use in the prevention and/or treatment of viral infections: Wherein X, Y, Z, T, R1a and R1b are as defined in claim 1.
摘要翻译： 本发明涉及用于预防和/或治疗病毒感染的式（I）化合物：其中X，Y，Z，T，R 1a和R 1b如权利要求1所定义。
-
12.发明授权Infectious cDNA of an approved vaccine strain of measles virus, use for immunogenic compositions 有权经证实的麻疹病毒疫苗株的感染性cDNA，用于免疫原性组合物公开(公告)号：US09005925B2
公开(公告)日：2015-04-14
申请号：US12219570
申请日：2008-07-24
IPC分类号： C07H21/04 , C07K14/005 , C12N7/00 , C12N15/86 , A61K39/00
CPC分类号： C12N7/00 , A61K39/00 , A61K2039/525 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N15/86 , C12N2760/18421 , C12N2760/18422 , C12N2760/18434 , C12N2760/18443 , C12N2795/10243
摘要： The invention relates to a cDNA molecule which encodes the nucleotide sequence of the full length antigenomic (+)RNA strand of a measles virus (MV) originating from an approved vaccine strain. It also contains the preparation of immunogenic compositions using said cDNA.
摘要翻译： 本发明涉及一种cDNA分子，其编码源自经批准的疫苗株的麻疹病毒（MV）的全长基因组（+）RNA链的核苷酸序列。 它还包含使用所述cDNA的免疫原性组合物的制备。
-
13.发明授权Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications 有权登革热和西尼罗病毒蛋白质和编码前述的基因，以及它们在疫苗，治疗和诊断应用中的应用公开(公告)号：US08859240B2
公开(公告)日：2014-10-14
申请号：US12476304
申请日：2009-06-02
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
摘要翻译： 本发明涉及表达来自西尼罗河脑炎病毒（WNV）或登革热病毒的不同免疫原的病毒载体的开发，其能够诱导针对WNV或登革热病毒感染的保护性体液和细胞免疫应答。 更具体地，本发明涉及来自WNV（分泌的包膜糖蛋白（E），异二聚体糖蛋白（pre-ME）和NSI蛋白）和登革病毒（分泌的包膜糖蛋白（e））的三（3）个抗原， 异二聚体糖蛋白（pre-me）和nsl蛋白）及其在疫苗，治疗和诊断应用中的应用。
-
14.发明申请RECOMBINANT MEASLES VIRUSES EXPRESSING EPITOPES OF ANTIGENS OF RNA VIRUSES - USE FOR THE PREPARATION OF VACCINE COMPOSITIONS 审中-公开表达RNA病毒抗原表位的重组测量病毒 - 用于制备疫苗组合物公开(公告)号：US20130052218A1
公开(公告)日：2013-02-28
申请号：US12700621
申请日：2010-02-04
IPC分类号： C12N7/01 , A61K39/165 , A61P31/12 , C12N15/86
CPC分类号： C12N15/86 , A61K39/12 , A61K39/165 , A61K39/21 , A61K47/6901 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N2740/16022 , C12N2740/16122 , C12N2760/18421 , C12N2760/18422 , C12N2760/18434 , C12N2760/18443 , C12N2760/18452 , C12N2770/24122 , Y02A50/388 , Y02A50/394
摘要： The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, said recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against said RNA virus or against both measles virus and against said RNA virus. It also relates to the use of said recombinant measles virus for the preparation of immunogenic composition.
摘要翻译： 本发明涉及表达源自确定的RNA病毒的抗原的异源氨基酸序列的重组麻疹病毒，所述重组麻疹病毒能够针对麻疹病毒或针对所述RNA病毒或针对所述RNA病毒引起体液和/或细胞免疫应答 麻疹病毒和针对所述RNA病毒。 它还涉及所述重组麻疹病毒用于制备免疫原性组合物的用途。
-
公开(公告)号：US09315482B2
公开(公告)日：2016-04-19
申请号：US13809761
申请日：2011-07-29
申请人： Pierre-Olivier Vidalain , Marianne Lucas-Hourani , Frédéric Tangy , Hélène Munier-Lehmann , Daniel Dauzonne
发明人： Pierre-Olivier Vidalain , Marianne Lucas-Hourani , Frédéric Tangy , Hélène Munier-Lehmann , Daniel Dauzonne
IPC分类号： C07D307/79 , C07D307/82 , C07D307/86 , C07D307/83 , C07D405/04 , C07D405/02 , C07D493/04
CPC分类号： C07D307/83 , C07D307/82 , C07D405/02 , C07D405/04 , C07D493/04
摘要： The invention relates to compounds of formula (I) for use in the prevention and/or treatment of viral infections: Wherein X, Y, Z, T, R1a and R1b are as defined in claim 1.
摘要翻译： 本发明涉及用于预防和/或治疗病毒感染的式（I）化合物：其中X，Y，Z，T，R 1a和R 1b如权利要求1所定义。
-
16.发明申请DENGUE AND WEST NILE VIRUSES PROTEINS AND GENES CODING THE FOREGOING, AND THEIR USE IN VACCINAL, THERAPEUTIC AND DIAGNOSTIC APPLICATIONS 有权登革热和西尼氏病毒蛋白质和基因编码前体及其在疫苗，治疗和诊断应用中的应用公开(公告)号：US20130089558A1
公开(公告)日：2013-04-11
申请号：US12476304
申请日：2009-06-02
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre-m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
摘要翻译： 本发明涉及表达来自西尼罗河脑炎病毒（WNV）或登革热病毒的不同免疫原的病毒载体的开发，其能够诱导针对WNV或登革热病毒感染的保护性体液和细胞免疫应答。 更具体地，本发明涉及来自WNV（分泌的包膜糖蛋白（E），异二聚体糖蛋白（pre-ME）和NSI蛋白）和登革病毒（分泌的包膜糖蛋白（e））的三（3）个抗原， 异二聚体糖蛋白（pre-me）和nsl蛋白）及其在疫苗，治疗和诊断应用中的应用。
-
公开(公告)号：US20100278872A1
公开(公告)日：2010-11-04
申请号：US12682457
申请日：2008-10-10
申请人： Anne Gauvrit , Frédéric Tangy , Marc Gregoire
发明人： Anne Gauvrit , Frédéric Tangy , Marc Gregoire
IPC分类号： A61K39/00 , A61K35/76 , C12N5/0784 , A61P35/00
CPC分类号： A61K39/165 , A61K39/12 , A61K2039/5154 , A61K2039/5254 , A61K2039/585 , C12N5/064 , C12N7/00 , C12N2760/18432 , C12N2760/18434
摘要： The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual.
摘要翻译： 本发明涉及至少一种减毒麻疹病毒用于制造用于治疗个体中恶性间皮瘤的药物的用途。
-
18.发明授权Dengue and West Nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications 有权登革热和西尼罗病毒蛋白质和编码前述的基因，以及它们在疫苗，治疗和诊断应用中的应用公开(公告)号：US07556812B2
公开(公告)日：2009-07-07
申请号：US11210960
申请日：2005-08-25
CPC分类号： A61K39/12 , A61K38/00 , A61K39/00 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C07K14/1825 , C12N15/86 , C12N2760/18443 , C12N2770/24122 , C12Q1/701 , Y02A50/386 , Y02A50/394 , Y02A50/53
摘要： The present invention relates to the development of viral vectors expressing different immunogens from the West Nile Encephalitis Virus (WNV) or the Dengue virus which are able to induce protective humoral and cellular immune responses against WNV or Dengue virus infections. More specifically, the present invention relates to three (3) antigens from WNV (the secreted envelope glycoprotein (E), the heterodimer glycoproteins (pre-M-E) and the NSI protein) and from Dengue virus (the secreted envelope glycoprotein (e), the heterodimer glycoproteins (pre- m-e) and the nsl protein) and their use in vaccinal, therapeutic and diagnostic applications.
摘要翻译： 本发明涉及表达来自西尼罗河脑炎病毒（WNV）或登革热病毒的不同免疫原的病毒载体的开发，其能够诱导针对WNV或登革热病毒感染的保护性体液和细胞免疫应答。 更具体地，本发明涉及来自WNV（分泌的包膜糖蛋白（E），异二聚体糖蛋白（pre-ME）和NSI蛋白）和登革病毒（分泌的包膜糖蛋白（e））的三（3）个抗原， 异二聚体糖蛋白（pre me）和nsl蛋白）及其在疫苗，治疗和诊断应用中的应用。
-
公开(公告)号：US09023643B2
公开(公告)日：2015-05-05
申请号：US12682457
申请日：2008-10-10
申请人： Anne Gauvrit , Frédéric Tangy , Marc Gregoire
发明人： Anne Gauvrit , Frédéric Tangy , Marc Gregoire
IPC分类号： C12N15/85 , C12N5/07 , C12N5/0784 , A61K39/12 , A61K39/00
CPC分类号： A61K39/165 , A61K39/12 , A61K2039/5154 , A61K2039/5254 , A61K2039/585 , C12N5/064 , C12N7/00 , C12N2760/18432 , C12N2760/18434
摘要： The present invention relates to the use of at least one attenuated measles virus for the manufacture of a medicament intended for treating malignant mesothelioma in an individual.
摘要翻译： 本发明涉及至少一种减毒麻疹病毒用于制造用于治疗个体中恶性间皮瘤的药物的用途。
-
20.发明授权Recombinant measles viruses expressing epitopes of antigens of RNA viruses—use for the preparation of vaccine compositions 有权表达RNA病毒抗原表位的重组麻疹病毒 - 用于制备疫苗组合物公开(公告)号：US09012214B2
公开(公告)日：2015-04-21
申请号：US12700621
申请日：2010-02-04
CPC分类号： C12N15/86 , A61K39/12 , A61K39/165 , A61K39/21 , A61K47/6901 , A61K2039/5256 , C07K14/005 , C12N7/00 , C12N2740/16022 , C12N2740/16122 , C12N2760/18421 , C12N2760/18422 , C12N2760/18434 , C12N2760/18443 , C12N2760/18452 , C12N2770/24122 , Y02A50/388 , Y02A50/394
摘要： The invention relates to a recombinant measles virus expressing a heterologous amino acid sequence derived from an antigen of a determined RNA virus, the recombinant measles virus being capable of eliciting a humoral and/or cellular immune response against measles virus or against the RNA virus or against both measles virus and against the RNA virus. It also relates to the use of the recombinant measles virus for the preparation of immunogenic compositions.
摘要翻译： 本发明涉及表达源自确定的RNA病毒的抗原的异源氨基酸序列的重组麻疹病毒，所述重组麻疹病毒能够引发针对麻疹病毒或针对RNA病毒的体液和/或细胞免疫应答 麻疹病毒和RNA病毒。 它还涉及重组麻疹病毒用于制备免疫原性组合物的用途。
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.026 秒)
